This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

This study has been withdrawn prior to enrollment.
Information provided by:
Novo Nordisk A/S Identifier:
First received: May 8, 2006
Last updated: June 26, 2012
Last verified: March 2012

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma

Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

Condition Intervention Phase
Acquired Bleeding Disorder Trauma Drug: activated recombinant human factor VII Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Mortality and Morbidity [ Time Frame: through day 30 ]

Secondary Outcome Measures:
  • All cause mortality
  • Hospital-free days
  • Number of transfusion units
  • Days free of renal replacement therapy
  • ICU-free days
  • Days free of ventilator support

Enrollment: 0
Study Start Date: May 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00323570

  Show 42 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Bartholomew Tortella, MD Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S Identifier: NCT00323570     History of Changes
Other Study ID Numbers: F7TRAUMA-1648
Study First Received: May 8, 2006
Last Updated: June 26, 2012

Additional relevant MeSH terms:
Wounds and Injuries
Blood Coagulation Disorders
Hemostatic Disorders
Pathologic Processes
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders processed this record on September 21, 2017